Long-Term Safety and Efficacy of Sublingual Asenapine Treatment for Schizophrenia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Neuropsychopharmacology Reports
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Long-term safety and efficacy of sublingual asenapine for the treatment of schizophrenia: A phase III extension study with follow-up for 52 weeks (P06125)-Secondary publication
Neuropsychopharmacol Rep 2023 May 25;[EPub Ahead of Print], T Kinoshita, Y Takekita, S Hiraoka, F Tamura, Y IwamaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.